Australian Study: Closed-Loop Insulin Pumps Boost Mental Health in Type 1 Diabetes

A study from Australia has found that hybrid closed-loop (HCL) insulin pump therapy — often called an "artificial pancreas" system — delivers meaningful psychological benefits for adults living with type 1 diabetes (T1D), not just better blood sugar numbers. Researchers at Deakin University's Institute for Health Transformation in Geelong, Victoria, discovered that patients using the MiniMed™ 670G system reported improved emotional well-being, less diabetes-related distress, and significantly reduced fear of low blood sugar after just six months.

What the Researchers Did

This was a rigorous multicenter, randomized controlled trial — considered the gold standard of medical research. A total of 120 adults with type 1 diabetes (average age 44 years) were randomly assigned to either 26 weeks of hybrid closed-loop therapy or standard therapy, which included insulin pumps or multiple daily injections without real-time continuous glucose monitoring (CGM). Crucially, the research team tracked not just blood sugar levels, but also psychological outcomes including diabetes distress, fear of hypoglycemia, positive well-being, treatment satisfaction, and quality of life.

Key Findings

The results were encouraging on the mental health front:

• Improved well-being in just 13 weeks: Patients using HCL therapy reported significantly better diabetes-specific positive well-being compared to the standard therapy group — an improvement that held steady through the full 26 weeks.
• Less diabetes distress at 6 months: By week 26, HCL users showed a statistically significant reduction in diabetes distress, the emotional burden that comes from managing a demanding chronic condition every single day.
• Reduced fear of hypoglycemia: HCL users reported less worry about low blood sugar and less need to deliberately keep their glucose levels higher than recommended just to avoid dangerous lows. For context, a low blood sugar episode in the US is typically defined as below 70 mg/dL (3.9 mmol/L), with serious lows falling under 54 mg/dL (3.0 mmol/L).
• Fewer perceived high blood sugar episodes: Patients on HCL therapy felt they were experiencing fewer unacceptably high glucose levels — readings that, by American Diabetes Association (ADA) standards, would be above 180 mg/dL (10.0 mmol/L) after meals.

Not everything improved, however. The HCL system did not produce significant gains in overall treatment satisfaction, general quality of life, or hypoglycemia awareness compared to standard therapy.

How This Compares to US Guidelines

The ADA's 2024 Standards of Care strongly recommend hybrid closed-loop systems for people with type 1 diabetes, citing benefits for time-in-range and A1C reduction. What this Australian study adds is compelling evidence that the psychological payoff — reduced anxiety, less burnout, better daily outlook — begins within just three months of starting HCL therapy. This supports the ADA's broader push to consider mental health as an essential component of diabetes care, not an afterthought.

Why This Matters for US Patients

Living with type 1 diabetes is relentlessly demanding. Studies consistently show that diabetes distress affects up to 45% of people with T1D in the United States. If you or a loved one has been considering an upgrade to a closed-loop system like the MiniMed 780G, Omnipod 5, or Tandem Control-IQ — which are the currently available HCL options in the US — this Australian research suggests the mental health benefits may arrive sooner than you expect. Talk to your endocrinologist about whether HCL therapy is right for your situation, including insurance coverage options, since access remains an equity challenge across the US.

Source: Halliday, Russell-Green, Lam. "Six months of hybrid closed-loop therapy improves diabetes-specific positive well-being, and reduces diabetes distress and fear of hypoglycemia." BMJ Open Diabetes Research & Care, 2024. PMID: 39797667. DOI: 10.1136/bmjdrc-2024-004428. Trial Registry: ACTRN12617000520336.